Back

Title
  • Possible Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Reducing Effects of Blood Glucose and also Blood Pressure
Creator
    • Bando, Hiroshi
Rights
  • © 2020 Bando H. This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
Subject
  • Other Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
  • Other Phlorizin
  • Other Antihypertensive Agents (AHA)
  • Other Cardiovascular Event
  • Other Blood Pressure
Description
  • Other Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) has been in focus for the pharmacotherapy of diabetes. SGLT2i contributes to decreasing blood pressure (BP) to some degree. BP changes were analyzed in 4 well-known mega-studies. They are Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58. The ultimate goal of antihypertensive and hypoglycemic agents is not the achievement of target values, but the suppression of cardiovascular events. SGLT-2i show excellent strategy for event suppression and adjunct method for hypertension.
Publisher Asploro
Date
    Issued2020-08-28
Language
  • eng
Resource Type journal article
Version Type VoR
Identifier URI http://repo.lib.tokushima-u.ac.jp/115284
Relation
  • isIdenticalTo DOI https://doi.org/10.36502/2020/ASJBCCR.6210
Journal
    • ISSN 2582-0370
      • Asploro Journal of Biomedical and Clinical Case Reports
      • Volume Number3 Issue Number3 Page Start186 Page End190
File
Oaidate 2023-06-26